Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
7.80
+0.07 (0.91%)
Jul 31, 2026, 4:00 PM EDT - Market closed
Cartesian Therapeutics Employees
Cartesian Therapeutics had 75 employees as of December 31, 2025. The number of employees increased by 9 or 13.64% compared to the previous year.
Employees
75
Change (1Y)
9
Growth (1Y)
13.64%
Revenue / Employee
$23,667
Profits / Employee
-$2,023,653
Market Cap
229.18M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 75 | 9 | 13.64% | 75 | 0 |
| Dec 31, 2024 | 66 | 28 | 73.68% | 66 | 0 |
| Dec 31, 2023 | 38 | - | - | 37 | 1 |
Related Stocks
| Company Name | Employees |
|---|---|
| MacroGenics | 293 |
| Capricor Therapeutics | 231 |
| ProQR Therapeutics | 187 |
| Entrada Therapeutics | 152 |
| Coherus Oncology | 145 |
| Adagene | 128 |
| AC Immune | 122 |
| Orchestra BioMed Holdings | 86 |
RNAC News
- 4 weeks ago - Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewsWire
- 7 weeks ago - Cartesian Therapeutics Announces New Employment Inducement Grant - GlobeNewsWire
- 7 weeks ago - Cartesian Therapeutics Transcript: AGM 2026 - Transcripts
- 7 weeks ago - Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases - GlobeNewsWire
- 2 months ago - Cartesian Therapeutics secures up to $150M financing from K2 HealthVentures - TheFly
- 2 months ago - Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027 - GlobeNewsWire
- 2 months ago - Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - GlobeNewsWire
- 2 months ago - Cartesian Therapeutics price target lowered to $25 from $30 at H.C. Wainwright - TheFly